Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636306 | 0.85 | MCHR1 (0.58) | MCHR1 | |
| SCHEMBL4287740 | 0.85 | MCHR1 (0.58) | MCHR1 | |
| SCHEMBL4578849 | 0.83 | MCHR1 (0.62) | MCHR1 | |
| SCHEMBL1665871 | 0.83 | MCHR1 (0.62) | MCHR1 | |
| SCHEMBL1749572 | 0.83 | MCHR1 (0.76) | MCHR1 | |
| SCHEMBL13558242 | 0.82 | USP2 (0.55) | MCHR1 | |
| SCHEMBL1750252 | 0.81 | MCHR1 (0.78) | MCHR1 | |
| SCHEMBL12529830 | 0.81 | MCHR1 (0.89) | MCHR1 | |
| SCHEMBL1750361 | 0.81 | MCHR1 (0.81) | MCHR1 | |
| SCHEMBL12530893 | 0.81 | MCHR1 (0.78) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299104-B2 | Melanin hormone antagonist; therapy for obesity, type-2 diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7319108-B2 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | CYP11B1, CYP11B2, GPR119 | MCHR1 1625/4885USP28 3132/4885 |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | MCHR1 1625/4885USP28 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.